|
Canada-0-RECUPERATION ไดเรกทอรีที่ บริษัท
|
ข่าว บริษัท :
- INDICATIONS AND USAGE DOSAGE AND ADMINISTRATION ADVERSE . . .
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use RYTELO safely and effectively See full prescribing information for
- RYTELO® (imetelstat) HCP Website | RYTELOHCP
RYTELO® (imetelstat) is indicated for treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia
- Rytelo: Package Insert Prescribing Information MOA
Rytelo package insert prescribing information for healthcare professionals Includes: indications, dosage, adverse reactions and pharmacology
- Rytelo, INN-imetelstat sodium
Rytelo 188 mg powder for concentrate for solution for infusion is a clear, 10 mL Type 1 glass vial with a chlorobutyl rubber stopper and an aluminium flip-off seal with a royal blue plastic cap
- DailyMed - RYTELO- imetelstat sodium injection, powder . . .
RYTELO for injection contains imetelstat, an oligonucleotide telomerase inhibitor for intravenous use Imetelstat sodium is a white to off-white or slightly yellow, amorphous, solid powder
- label - Food and Drug Administration
RYTELO (imetelstat) for injection is a sterile, preservative-free, white to off-white or slightly yellow lyophilized powder for intravenous infusion after reconstitution and dilution
- Rytelo (imetelstat) dosing, indications, interactions . . .
Medscape - Myelodysplastic syndrome dosing for Rytelo (imetelstat), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy lactation schedules, and cost information
- RYTELO (imetelstat), FDA Approved for Treatment of Patients . . .
Biologics has been selected as a specialty pharmacy for RYTELO (imetelstat) for the treatment of adult patients with Low- to Intermediate-1 Risk Myelodysplastic Syndromes (MDS) with Transfusion-dependent Anemia
- Rytelo: Uses, Dosage, Side Effects, Warnings - Drugs. com
Rytelo (imetelstat) is an injectable telomerase inhibitor that may be used to treat adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia
- FDA approves imetelstat for low- to intermediate-1 risk . . .
On June 6, 2024, the Food and Drug Administration approved imetelstat (Rytelo, Geron Corporation), an oligonucleotide telomerase inhibitor, for adults with low- to intermediate-1 risk
|
|